Parkinson's disease, a progressive and degenerative brain condition, affects more than 1 percent of individuals over the age of 60 worldwide, leading to symptoms such as slow movements, muscle tremors, stiffness, and difficulty walking. Traditional treatments focus primarily on managing dopamine
With over 300 million people globally suffering from chronic hepatitis B, the disease presents a monumental challenge in the realm of public health. Traditional treatments have mainly focused on suppressing the virus rather than providing a cure, demanding lifelong therapy for many patients.
Ivan Kairatov is a distinguished figure in the biopharma industry, renowned for his expertise in tech and innovation within the field. With a robust background in research and development, Ivan has substantially influenced advancements in cellular therapies and drug development. Today, we delve
A groundbreaking study from Arizona State University (ASU) has discovered remarkable insights about a potentially new healing process prompted by necrosis, the premature death of cells. This unexpected phenomenon, observed in fruit flies known for their regenerative capabilities, may have profound
Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key player
The medical landscape has been witnessing a groundbreaking shift with the advent of novel therapies aimed at tackling some of the most challenging conditions. One such development is the Phase 1/2 clinical trial of Cabaletta Bio's CAR T-cell therapy, rese-cel (resecabtagene autoleucel), targeting
